Format

Send to

Choose Destination
J Clin Epidemiol. 2019 Jan 29. pii: S0895-4356(18)30727-3. doi: 10.1016/j.jclinepi.2019.01.009. [Epub ahead of print]

The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics.

Author information

1
Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, Sydney, Australia; Computational Health Informatics Program, Boston Children's Hospital, Boston, United States. Electronic address: adam.dunn@mq.edu.au.
2
Computational Health Informatics Program, Boston Children's Hospital, Boston, United States.
3
Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, Sydney, Australia.
4
Computational Health Informatics Program, Boston Children's Hospital, Boston, United States; Department of Biomedical Informatics, Harvard Medical School, Boston, United States.
5
Computational Health Informatics Program, Boston Children's Hospital, Boston, United States; Division of Emergency Medicine, Boston Children's Hospital, Boston, United States; Departments of Pediatrics and Emergency Medicine, Harvard Medical School, Boston, United States.

Abstract

OBJECTIVE:

To determine whether certain trial characteristics are associated with faster or more frequent inclusion in systematic reviews for drug interventions in type 2 diabetes.

STUDY DESIGN AND SETTING:

We examined trials included in systematic reviews published between 1 January 2007 and 1 January 2017. Primary outcomes were time between trial publication and first inclusion in a systematic review, and frequency of inclusion in systematic reviews over the study period. Multivariable Cox proportional hazards and regression models quantified associations with funding source, number of participants, trial conclusion, and journal impact factor.

RESULTS:

Among 668 trials, the median time to inclusion was 76.1 weeks. Time to inclusion was shorter for trials with industry funding (HR 1.39; 95% CI 1.13-1.71), more participants (HR 1.26; 95% CI 1.17-1.36), and published in higher impact factor journals (HR 1.28; 95% CI 1.14-1.45). The median frequency of inclusion was 3. Frequency of inclusion was greater for trials with industry funding (RR 2.36; 95% CI 2.11-2.64), more participants (RR 1.51; 95% CI 1.47-1.55), positive conclusions (RR 1.89; 95% CI 1.68-2.13), and published in higher impact factor journals (RR 1.13; 95% CI 1.08-1.18).

CONCLUSION:

Certain trial characteristics are associated with faster or more frequent trial inclusion in systematic reviews of type 2 diabetes.

KEYWORDS:

Type 2 diabetes; randomized controlled trials; systematic review as a topic

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center